Motoric Cognitive Risk Syndrome in Polypharmacy

J Am Geriatr Soc. 2020 May;68(5):1072-1077. doi: 10.1111/jgs.16380. Epub 2020 Feb 24.

Abstract

Objectives: Risk factors for motoric cognitive risk syndrome (MCR), a predementia syndrome characterized by slow gait and cognitive complaints, have been identified, but few are reversible. Polypharmacy is a potentially reversible risk factor for cognitive decline, but the relationship between MCR and polypharmacy has not been examined. Our aim was to compare the epidemiology of MCR and polypharmacy.

Design: Cross-sectional.

Setting: Community-based Health and Retirement Study cohort.

Participants: A total of 1119 adults 65 years and older (mean age = 74.7 ± 7.0 y; 59% female).

Measurements: Polypharmacy is defined as the use of five or more regularly scheduled medications. MCR is defined as cognitive complaints and slow gait in an individual without dementia.

Results: The prevalence of MCR among 417 participants with polypharmacy was 10%; it was 6% among 702 participants without polypharmacy. The odds of meeting MCR criteria in those with polypharmacy was 1.8 (confidence interval = 1.0-3.0; P = .035) compared with those without polypharmacy, even after adjusting for high-risk medication use.

Conclusion: Our results show the coexistence of MCR and polypharmacy in older adults, suggesting a potentially modifiable risk factor for dementia. J Am Geriatr Soc 68:1072-1077, 2020.

Keywords: motoric cognitive risk syndrome; polypharmacy; prevalence.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Cognitive Dysfunction / diagnosis*
  • Cognitive Dysfunction / epidemiology
  • Cross-Sectional Studies
  • Female
  • Health Surveys
  • Humans
  • Longitudinal Studies
  • Male
  • Polypharmacy*
  • Prevalence
  • Risk Factors
  • Syndrome
  • Walk Test / methods
  • Walking Speed*